OncoMatch/Clinical Trials/NCT06496373
Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer
Is NCT06496373 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies multiple treatments including Fixed neoantigen tumor vaccine and personalized neoantigen tumor vaccine for pancreatic cancer resectable.
Treatment: Fixed neoantigen tumor vaccine · personalized neoantigen tumor vaccine · PD-1 inhibitor — This study primarily aims to assess the safety and tolerability of XP-004 personalized mRNA vaccines encoding tumor neoantigens combined with PD-1 inhibitor as adjuvant therapy for chemotherapy-intolerant patients following radical pancreatic cancer resection. Secondary objectives focus on evaluating preliminary efficacy through three parameters: 1) XP-004-induced antigen-specific CD4+/CD8+ T cell activation levels, 2) recurrence-free survival (RFS), and 3) overall survival (OS) in post-operative pancreatic cancer patients receiving this combination therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Prior therapy
Must have received: surgery — radical
have undergone radical surgery for pancreatic malignant tumors for 1-3 months
Cannot have received: chemotherapy
Has had chemotherapy...within 4 weeks prior to the first administration of the study drug
Cannot have received: traditional Chinese medicine with antitumor indications
Has had...traditional Chinese medicine with antitumor indications...within 4 weeks prior to the first administration of the study drug
Cannot have received: other antitumor therapies deemed to conflict with the current treatment by the investigator
Has had...other antitumor therapies deemed to conflict with the current treatment by the investigator within 4 weeks prior to the first administration of the study drug
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06496373 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, traditional Chinese medicine with antitumor indications, other antitumor therapies deemed to conflict with the current treatment by the investigator disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages